Myocarditis and Myocardial Injury in Long COVID Syndrome: A Comprehensive Review of the Literature

The repercussions of coronavirus disease 2019 (COVID-19) have been devastating on a global scale. Long COVID, which affects patients for weeks or even months after their initial infection, is not limited to individuals with severe symptoms and can affect people of all ages. The condition can impact various physiological systems, leading to chronic health conditions and long-term disabilities that present significant challenges for healthcare systems worldwide. This review explores the link between long COVID and cardiovascular complications such as myocardial injury and myocarditis. It also highlights the prevalence of these complications and identifies risk factors for their development in long COVID patients. Myocardial injury occurs due to direct cellular damage and T-cell-mediated cytotoxicity resulting in elevated cardiac biomarkers. Diagnostic techniques like electrocardiogram, troponin level testing, and magnetic resonance imaging can help identify myocarditis, but endomyocardial biopsy is considered the gold-standard diagnostic technique. Guideline-directed medical therapy is recommended for COVID-19 myocarditis patients for better prognosis while being monitored under comprehensive care management approaches. Therefore, it's critical to develop effective screening techniques specifically for vulnerable populations while conducting further research that addresses the effects of long COVID on society's physical health.


Introduction And Background
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a viral infection that results in coronavirus disease 2019 , began in Wuhan, China, in December 2019. Since then, this virus has had severe consequences for various organ systems within the human body. Despite numerous attempts by governments worldwide to reduce the spread of COVID-19, it has continued to ravage populations globally and has resulted in a devastating pandemic. The COVID-19 pandemic has had a significant impact on humanity and caused millions of deaths worldwide. As of June 1st, 2023, data from the World Health Organization (WHO) reveals that over 761 million cases of COVID-19 have been reported globally, resulting in nearly 6.9 million fatalities [1]. It is worth noting that despite the alarming statistics, the mortality rate for COVID-19 remains less than 1%, and this can be attributed mainly to severe acute respiratory syndrome and multiple organ dysfunction [2]. It is essential to recognize that, among other potential complications related to COVID-19, myocarditis is particularly concerning as it causes inflammation of the heart muscle, leading to life-threatening conditions such as acute non-ischemic myocardial injury, systolic heart failure, cardiogenic shock, and arrhythmias. Myocarditis can occur as a result of direct viral damage or an overly reactive immune response [3]. Indeed, some individuals infected with COVID-19 have even succumbed to this condition [4]. Given these serious findings, there is an urgent need for continuous monitoring and research regarding COVID-19's clinical manifestations to ensure optimal patient care strategies are implemented worldwide.
Myocarditis is usually caused by various factors, such as viral and bacterial infections. Myocyte destruction occurs due to myocarditis, which can ultimately result in cardiomyopathy, heart failure, and sudden cardiac death (due to arrhythmias mainly) [4].
Those who have contracted the virus may present with a broad spectrum of symptoms that vary in their severity. The manifestation of these symptoms may range from being inconspicuous or absent to being

Review Rationale
It is of utmost importance to comprehend the correlation between long COVID and myocarditis or myocardial injury, as it plays a critical role in the formulation of efficacious diagnostic and treatment methodologies. Given the paucity of research on this matter, a complete analysis of the existing literature can prove invaluable in identifying areas where information is lacking and where further investigations are warranted. By conducting a comprehensive review, one can identify potential avenues for scientific inquiry that will shed light on this crucial area of study.

Epidemiology and prevalence of long COVID syndrome
Amidst the COVID-19 pandemic, patients have reported experiencing enduring and incapacitating symptoms, including but not limited to cognitive dysfunction, fatigue, and respiratory distress. The aforementioned concerns were extensively deliberated across various social media channels. It is noteworthy that individuals who undergo severe illness, hospitalization, or intensive treatment may develop a condition known as post-intensive care syndrome (PICS), which can lead to diminished functionality for a duration of up to one year following discharge. The aforementioned phenomenon poses a challenge in discerning the symptoms that are linked to post-COVID-19 conditions like long COVID, long-haul COVID, post-acute sequelae of SARS-CoV-2 infection (PASC), and chronic COVID [9], as these conditions require a considerable amount of time to manifest. The term "long COVID" has been popularized by patients on social media platforms such as Twitter (Twitter, Inc., San Francisco, California, United States) and Reddit (Reddit Inc., San Francisco, California, United States), as medical experts have yet to establish an official diagnosis for the persistent symptoms of COVID-19. Therefore, these virtual discussion boards have served as a medium for individuals to exchange their personal accounts and establish relationships with others who are encountering comparable obstacles in their journey toward rehabilitation [10].
According to the World Health Organization (WHO), post-COVID-19 condition is defined as symptoms that are inexplicable by any alternative diagnosis, last for at least two months, impact day-to-day functioning, and occur three months from the onset of COVID-19 [11]. Many cohort studies with questionnaires have been used to follow up on patients fitting this criteria. One cohort of 234 participants 3-9 months after their initial acute illness was surveyed to find that 30% of them reported symptoms six months later and 30% also reported a worsened quality of life [12]. Many retrospective cohorts of this type were conducted early in the pandemic. Another cohort study performed an anonymous online survey of 3,762 participants from 56 different countries. It was found that 55.5% of participants experienced cognitive dysfunction in their seventh month after illness, and 45.2% reported the need to reduce their work schedule. The study collected a total of 66 reported symptoms that were traced over seven months [13].
Lung diffusion capacity and health-related quality of life (HRQoL) were also examined by a prospective cohort performed on 101 patients six weeks post discharge. Seventy-two percent of patients showed a diffusing capacity of the lungs for carbon monoxide (DLCO) <80% predicted value, indicating a limitation of lung diffusion. Even non-critical COVID-19 pneumonia survivors report decreased HRQoL [14]. Another cohort measured fatigue in study participants using the Chalder Fatigue Score (CFQ-11) and found that over 50% of participants reported fatigue (not associated with initial disease severity) approximately 10 weeks after their initial illness [15]. A similar cohort found 34.8% of their patients to have at least one symptom seven months after symptom onset. It was observed that anosmia and/or diarrhea during the initial acute illness were associated with a higher chance of incurring longer-term symptoms [16]. Cardiac outcomes were also observed in a cohort that performed cardiovascular magnetic resonance (CMR) imaging on 100 patients at a median time interval of 71 days after their diagnosis; 60% of their patients showed ongoing myocardial inflammation [17]. A cohort study performed in a single hospital found additional symptoms such as alopecia in 28.6% of their participants, along with a small number of patients reporting a recent diagnosis of hypertension since their initial acute illness [18].
Long COVID can present with a constellation of symptoms with variable onset and intensity, making it difficult to accurately estimate its prevalence. The diagnosis will require a robust patient history and followup. A prospective cohort performed as a telephone survey sampled 1250 post-COVID-19 discharge patients, of whom 488 responded to the telephone survey. Of the respondents, 159 (32.6%) reported cardiopulmonary symptoms 60 days after being discharged. The authors of this cohort write about the limitations, as half of their sample did not complete their follow-up. It was also noted that although most patients went to a primary care physician (PCP) post discharge, 20% of the patients had no primary care follow-up visit within two months post discharge [19]. One specific cohort demonstrated that there was no significant difference in the risk of any feature of long COVID between unvaccinated and vaccinated patients post acute illness [20]. An additional cohort surveyed by trained physicians approximately 111 days after discharge compared two patient groups: patients requiring ICU care and those managed in the hospital wards. The study concluded that the appearance of persistent symptoms in both groups was similar and that no significant difference in HRQoL exists between the two patient groups [21].
In 2020, Italy set up a specialized outpatient clinic to monitor the recovery of discharged patients and captured a sample size of 31,845 confirmed cases. The patients were all discharged following the WHO criteria for discontinuation of quarantine, and 71.4% of the cases sampled had symptoms 60 days after discharge, while 87.4% reported experiencing at least one symptom. The authors of the study, Carfì et al., note that there may be a bias due to patient self-reporting and a lack of details on the severity of symptoms [22]. According to a study by the United Kingdom (UK) Office for National Statistics, one in five participants who tested positive for COVID-19 had symptoms that lasted for five weeks or longer. Approximately one in 10 participants exhibited symptoms for 12 weeks or longer [23]. The ONS also released a census of 1.9 million UK residents who self-reported symptoms beyond four weeks from their first confirmed or suspected COVID-19 infection [24]. The UK government published its latest statistics on an online webpage where they have notated 19,224,278 total first infections, with 1.53 million cases of reinfection [25]. This would correlate to approximately 10% of confirmed cases presenting with symptoms of long COVID.
Without more precise ways of diagnosing long COVID, it will remain difficult to estimate its prevalence. Some studies have demonstrated that patients with long COVID have an elevated humoral antibody response to SARS-CoV-2 viral pathogens with increased levels of interleukin-8 (IL-8), chemokine ligands 4 (CCL4), and other soluble immune mediators. Cross-reactivity with a herpesvirus was observed [26]. The future development of objective biomarkers to diagnose long COVID is highly necessary. According to the WHO global COVID-19 dashboard, as of April 2023, there have been 762,201,169 cumulative cases of COVID-19 in the world so far [27]. Even the above-suggested 10% prevalence would prove to be a huge number of worldwide patients afflicted.

Cardiovascular complications in long COVID syndrome
The available data on long COVID syndrome is currently limited. Nonetheless, we have conducted a thorough literature review, which has documented evidence of myocarditis or myocardial injury in patients with COVID-19. Several studies have suggested that individuals with long COVID syndrome may be at increased risk for developing cardiovascular diseases such as myocarditis, arrhythmias, and heart failure [28,29].
A study reported that cardiac damage, shock, and arrhythmia were prevalent among hospitalized patients. Specifically, the incidence of acute cardiac damage, shock, and arrhythmia was 7.2%, 8.7%, and 16.7%, respectively, among the cohort comprising 138 hospitalized patients [28]. It is noteworthy that these occurrences were found to be more frequent in patients who required intensive care. Additionally, a study conducted by the United States Department of Veterans Affairs Health Services revealed an increased incidence of cardiovascular and metabolic diseases in over 73,000 non-hospitalized COVID-19 patients who experienced death within a month after contracting the virus. Furthermore, a UK-based study on an extensive cohort involving nearly 48,000 hospitalized COVID-19 patients showed they had a three-time higher risk for cardiovascular events four months after discharge compared to non-hospitalized individuals. These reports highlight how coronaviruses may not only affect a person's respiratory system but also pose significant implications for their cardiovascular health. The study underscores the need to further evaluate and undertake appropriate treatment protocols to mitigate its effects on heart health. Notably, both studies suggest that men are at higher risk for such post-long COVID-related complications related to cardio events [29].
As per a comprehensive literature review on the aftermaths of long COVID syndrome, clinical outcomes, and plausible molecular mechanisms, it has been found that one-fourth of patients who were hospitalized due to COVID-19 suffered from myocardial injury, which increased their likelihood of mortality. Furthermore, post-mortem histological examinations of COVID-19 patients revealed myocardial hypertrophy in a staggering 92.9% of cases, mild to severe coronary artery atherosclerosis in all cases examined (100%), and localized myocardial fibrosis in 21.4% of cases [30].
A review concluded that the persistent nature of cardiovascular symptoms in long COVID patients is a significant concern. This is highlighted by current evidence showing ongoing heart-related issues such as pain, rapid heart rate, and breathlessness, even after acute symptoms have resolved. The evidence of myocardial injury, persistent elevation of troponin levels, myocarditis-like scarring, and late gadolinium enhancement in a non-ischaemic myocarditis-like pattern further supports the seriousness of the impact on the cardiovascular system [31].
The findings of a research investigation involving 26 collegiate athletes who had experienced mild or asymptomatic COVID-19 infection indicated that 15% of the subjects were diagnosed with myocarditis through the use of cardiac magnetic resonance imaging (MRI), while 30.8% displayed indications of previous myocardial damage [32]. A multidisciplinary clinic report showed that tachycardia and palpitations were persistent in 25-50% of patients 12 weeks after COVID-19 and in 9% of patients six months after COVID-19 [33].
In conclusion, there is significant evidence to suggest a persistent and impactful effect of COVID-19 on cardiovascular health. These effects include prolonged chest pain, palpitations, and dyspnea, as well as more severe complications like arrhythmias, pericarditis, and myocardial damage. Cardiac involvement is seen in a large proportion of patients post COVID-19, with some experiencing cardiac inflammation, regional scarring, and pericardial enhancement. This highlights the importance of long-term cardiovascular monitoring and care in COVID-19 recovery [31-52] ( Table 1).  In COVID-19 patients, heightened levels of cardiac biomarkers, for example, cardiac troponin, have been discovered to indicate cardiac injury. This is closely associated with more severe disease progression and has the potential to predict hospitalization in the ICU and loss of life. The systemic inflammation and cytokine storm typical of COVID-19 have been linked to an increase in levels of inflammatory biomarkers such as IL-6 and C-reactive protein (CRP) [54]. These mediators have the potential to cause myocardial depression in cases where there is systemic hyper-inflammation, such as sepsis. Additionally, it has been observed that direct viral invasion of the myocardium can be boosted by an increased expression of human angiotensin converting enzyme-2 (ACE2) receptor in the myocardium due to the binding between spike proteins of COVID-19 and numerous viral particles entering cardiac fibers [55].

Source
Numerous studies have demonstrated that human coronaviruses are linked to myocarditis in individuals of all ages. Once inside the human body, COVID-19 attaches itself to the ACE2 membrane protein by means of its spike protein. ACE2 is found in ciliated columnar epithelial cells of the respiratory tract, type II pneumocytes, and cardiomyocytes. This suggests that COVID-19 may pose a risk to human heart health, particularly in cases where ACE2 expression has been elevated due to heart failure. Nevertheless, it should be noted that viral receptor presence alone does not always serve as an accurate predictor of viral tropism [2].
The molecular pathophysiology of COVID-19 myocarditis involves the virus binding to ACE2 through its spike protein, which requires cleavage at the S1/S2 and S2 sites. A serine protein named transmembrane protease, serine 2 (TMPRSS2) mediates this cleavage. After entering human cells, COVID-19 may impede stress granule formation via its accessory protein, thus enabling replication and damage. Hepatocyte growth factor (HGF) produced by the heart can prime T-lymphocytes for viral antigens and cardiotropism, leading to CD8+ T-lymphocyte migration to cardiomyocytes and myocardial inflammation from cell-mediated cytotoxicity. The cytokine storm syndrome further amplifies T-lymphocyte activation, resulting in additional cytokine release and immune activation with subsequent myocardial injury [2].

Risk factors of myocarditis in patients with long COVID syndrome
There is a dearth of research on the risk factors associated with myocarditis in patients with long COVID syndrome [56]. However, some studies suggest that certain factors may increase the risk of myocarditis or myocardial injury in these patients.
Although the exact relationship between risk factors and post-COVID-19-syndrome-associated myocarditis has not yet been discovered, most patients who showed signs and symptoms of myocarditis had a past medical history of hypertension, obesity, diabetes mellitus [57], chronic kidney disease, chronic obstructive pulmonary disease, asthma, chronic liver disease, cerebral vascular accidents, coronary artery disease, and structural heart disease [58]. Some of the common risk factors of myocarditis in patients with long COVID syndrome have been shown in Figure 1. Studies also report that most patients did not have a previously identified comorbid condition (50%); hypertension was the most predominant comorbidity in those patients with a past medical history (33%) [58,59]. Certain nonmodifiable factors have been determined through multiple studies, for instance, age and ethnicity. Many studies report that the male gender is more susceptible to developing post-COVID-19 myocarditis; two age groups were more prevalent: 12-17 years and men above 50 [60,61]. A study has also found that the incidence is higher in Asians, African Americans, Native Americans, Hispanics, and minority ethnic groups [62].
Exercise has reportedly been shown to exacerbate cardiac dysfunction in people who experience post-COVID myocarditis. Accelerated viral replication, more severe inflammation, and cellular death are thought to be the causes of this dysfunction. Being an athlete was probably a contributing aspect as well [62,63].

Clinical presentation of myocarditis in patients with long COVID syndrome
Long COVID syndrome encompasses a wide range of symptoms that persist for more than two months after the initial COVID-19 infection and cannot be explained by any other diagnosis. These symptoms include, but are not limited to, prolonged fatigue, sensory deficits, neurocognitive deficits, and cardiovascular manifestations such as myocarditis and arrhythmias. Common cardiovascular symptoms during this period include chest pain, palpitations, shortness of breath with exertion, presyncope, fatigue, and pedal edema. Despite these notable cardiovascular effects associated with long COVID syndrome, the underlying causes remain unclear.
Long COVID syndrome significantly increases the risk of cardiovascular complications, underscoring the need for careful cardiac monitoring in COVID-19 patients. However, more extensive prospective studies are required for more precise estimates [64]. One report described the first instance of acute cardiac injury directly associated with myocardial localization of SARS-CoV-2. The patient had flu-like prodrome which swiftly degenerated into respiratory distress, hypotension, and cardiogenic shock [65]. The sufferer complained of exacerbating dyspnea, a constant cough, and fatigue for four days. The nasopharyngeal swab was conclusive for COVID-19 on the real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay. In three hours, LVEF dropped from 34% to 25%. According to convention, in non-ischaemic cardiogenic shock, an endomyocardial biopsy was done, which revealed viral particles in structurally damaged interstitial cells. Cardiogenic shock clinically imitated fulminant myocarditis and was managed in accordance with standard protocols [65].
In a cohort study comprising 100 recovered COVID-19 patients, cardiac MRI revealed that 78% had cardiac involvement, with continuous myocardial inflammation present in 60%. This occurrence was found to be independent of pre-existing health conditions, the severity and overall course of the acute illness, and the time elapsed since the initial diagnosis. Eligibility for participation in this study was determined by a period of at least two weeks following the original diagnosis, during which respiratory symptoms cleared up and swab test results came back negative. Compared to control groups, patients who had recovered from COVID-19 exhibited a decreased LVEF and right ventricular ejection fraction (RVEF) while simultaneously having an increased left ventricular volume. These individuals also reported experiencing symptoms such as atypical chest pain, palpitations, dyspnea, and fatigue; 25 patients even noted experiencing these symptoms during activities that would typically cause no discomfort or exhaustion [66].
Another case report discussed the case of a 31-year-old patient with fluctuating symptoms of myopericarditis which was diagnosed based on cardiac MRI and elevated troponin levels, one year after testing positive for COVID-19, thus meeting the criteria of long COVID syndrome. He developed severe chest pain radiating to the scapular region, although no signs of infarction were seen on the ECG. Echocardiogram revealed myopericarditis with an LVEF of 43%. Due to persistent cardiac manifestations like tachycardia, dyspnea, and fatigue, cardiac MRI and scintigraphy were performed. MRI revealed global myocardial hyperintensity. Scintigraphy revealed cold areas, which were suggestive of hyperinflammation [67].
Based on the limited studies available about patients suffering from myocarditis as a sequelae of long COVID syndrome, the common clinical manifestations that the patients presented with were dyspnea, chest pain, palpitations, and a persistent cough. It is noteworthy to mention that general exhaustion remained the most common symptom reported across all the studies.

Diagnosis and investigations
The diagnosis of myocarditis heavily relies on clinical features [68]. The symptoms associated with SARS-CoV-2-induced myocarditis can vary considerably among patients. Although some may experience mild signs such as shortness of breath and fatigue, others may feel chest pain or tightness upon exertion [2,69,70]. In more severe cases, there may be a deterioration in the condition characterized by tachycardia and indications of acute heart failure such as cardiogenic shock. Additionally, the development of right-sided heart failure symptoms like peripheral edema, elevated jugular venous pressure, and right upper quadrant discomfort has been observed [71]. Fulminant myocarditis emerges within two to three weeks of viral exposure and is considered the most severe form [72]. Early signs of fulminant myocarditis are similar to those of sepsis, including fever, low pulse pressure, cold or patchy extremities, and sinus congestion. As a result, it is crucial for healthcare providers to recognize the various clinical presentations associated with myocarditis promptly. They should conduct a comprehensive assessment of patients who present with potential symptoms to guarantee a timely diagnosis and appropriate management.

Inflammatory and other biomarkers
When a patient is suspected of having myocarditis, several blood tests are performed to determine the levels of different markers, such as lactate and inflammatory markers like CRP, erythrocyte sedimentation rate (ESR), and procalcitonin. These levels are often elevated in myocarditis patients, which could be indicative of an infection. During diagnosis, it's crucial to differentiate between fulminant myocarditis and sepsis because the fluid resuscitation protocol that is commonly used in treating sepsis can lead to fluid overload, worsening the condition in fulminant myocarditis patients. Cardiac enzyme levels like cardiac troponin I, cardiac troponin T, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and BNP should be evaluated when a patient is admitted to the hospital since they're typically increased in acute myocardial harm caused by myocarditis with possible ventricular dilation. Recent studies [69,70,71] have found that COVID-19infected individuals with myocarditis also have increased levels of troponin and NT-proBNP. Although a negative troponin result may not completely eliminate the possibility of being diagnosed with acute myocarditis, it can still be useful during the acute phase; especially if serial high-sensitivity cardiac troponin tests are negative, since this significantly lowers the probability of diagnosing acute myocarditis. Furthermore, increases in NT-proBNP levels may also occur in COVID-19-infected patients due to potential side effects from severe respiratory illnesses leading to myocardial stress [73].

Cardiac tests
Myocarditis may exhibit ECG irregularities that are frequently linked with pericarditis, such as ST elevation and PR depression. However, these findings are not reliable enough to diagnose the condition and should not be solely relied upon to rule it out. A COVID-19-related myocarditis case serves as an example where neither PR depression nor ST elevation was evident [69]. Myocarditis can also cause other ECG abnormalities, such as new-onset bundle branch block, bradyarrhythmia with advanced atrioventricular nodal block, QT prolongation, pseudo infarct pattern, and premature ventricular complexes [68].
Cardiac MRI is considered the optimal noninvasive diagnostic test due to its high specificity in detecting myocarditis as well as its superior sensitivity of 75%. It is recommended to use the Lake Louis standards when analyzing cardiac MRI images. Previous research is in favor of this approach [52,74]. The criteria proposed involves the integration of T2-weighted images with early and late gadolinium enhancement in order to detect the presence of myocardial edema, hyperemia, myocardial necrosis, and myocardial fibrosis. One limitation of cardiac MRI is its inability to differentiate between inflammation caused by an autoimmune response to the virus and inflammation resulting from a viral infection of the heart, as noted in reference 74. Furthermore, the utilization of cardiac MRI may be limited in individuals who present with significant myocarditis resulting in cardiogenic shock or unstable hemodynamics [75]. Additionally, these individuals may require mechanical ventilation or experience tachyarrhythmias. Under the given circumstances, it may be deemed more advantageous.

Prognosis and outcomes
The occurrence of myocarditis among individuals who contract COVID-19 is associated with a less favorable prognosis regarding the progression and resolution of the COVID-19 illness. However, the extended-term outlook for mild instances of myocarditis remains uncertain and requires further investigation [68,76]. Researchers indicate that target tissue fibrosis and microangiopathy may result from immune activation and dysfunction, having long-lasting impacts on the patients who are impacted. As a result of worries that COVID-19 could cause myocardial damage, researchers began imaging survivors of the virus using cardiac MRI. They observed a significantly elevated occurrence rate (as high as 78%) of anomalies in patients who underwent cardiac MRI testing within the time frame of 37-71 days following their COVID-19 diagnosis [77].
As per a study conducted by German researchers, a significant proportion of individuals who survived the SARS-CoV-2 infection experienced persistent cardiac involvement even after two months of testing positive. Specifically, 78% of the survivors showed evidence of ongoing cardiac involvement, and 60% continued to display symptoms of myocarditis [14]. These individuals are at risk of developing chronic heart failure. Therefore, it is critical to determine individuals with cardiac involvement as soon as possible so that they can receive cardioprotective therapy and the proper follow-up measures. Nevertheless, similar complications did not occur in patients who had been vaccinated for COVID-19 [78].

Myocarditis and long COVID management and treatment
Myocarditis management and treatment in long COVID syndrome depends on the severity of symptoms, complication, onset, and hemodynamic stability vs. unstability.
Considerable uncertainty surrounds the COVID-19 infection. Similar to other conditions involving acute cardiac injury, the response is expected to vary significantly depending on various factors such as the type of myocardial injury mechanism, severity of the acute illness, therapeutic intervention administered, hemodynamic response, host characteristics, immune-mediated factors, as well as post-treatment care and monitoring [79].
It is recommended that patients experiencing heart failure as a result of COVID-19 myocarditis be treated in accordance with established medical guidelines. This involves the administration of ACE inhibitors, angiotensin receptor blockers (ARBs), angiotensin receptor-neprilysin inhibitors (ARNi), β-blockers, and diuretics [80]. The primary apprehension was that administering ACE inhibitors, ARBs, and ARNIs as a therapeutic intervention for COVID-19 patients could potentially result in unfavorable clinical outcomes owing to the pharmacological mechanisms of these medications. Nevertheless, recent observational studies have indicated that there is no statistically significant distinction in the treatment of patients with ACEi or ARB medication when compared to the cessation of such medications. Therefore, it is commonly advised to commence or persist with these medications throughout and after the illness [81,82].
The recommended course of action for managing patients diagnosed with fulminant myocarditis and experiencing cardiogenic shock involves the administration of inotropes and/or vasopressors during the acute phase, as well as mechanical circulatory support for longer-term management [83][84][85][86][87].
It is crucial to efficiently manage cardiac arrhythmias that are commonly linked with COVID-19 myocarditis, in order to minimize any negative health outcomes for patients. Temporary cardiac pacing may be necessary in instances of bradyarrhythmia, while tachyarrhythmias may be treated effectively with antiarrhythmic medications. In cases where patients are hemodynamically stable, the administration of βblockers may be deemed appropriate. Conversely, critically ill patients are typically prescribed amiodarone.
It is important to acknowledge that the use of amiodarone can result in QTc prolongation, particularly when used in conjunction with azithromycin or hydroxychloroquine, as noted in sources [86][87][88]. An alternative therapeutic approach may encompass the administration of either lidocaine infusions or oral flecainide [84][85][86]. In addition, there exist therapeutic options for the SARS-CoV-2 virus that require examination.
Some researchers have suggested the use of anti-inflammatory and anti-cytokine medications, such as IV immunoglobulin (IVIG) and high-dose steroids, due to the potential role of cytokine release syndrome in COVID-19 myocarditis. This recommendation is based on their investigation of the condition. The administration of high doses of steroids to COVID-19 patients has yielded inconsistent results. One retrospective study has shown an improvement in survival rates, while another trial has revealed a decrease in viral clearance and an increased vulnerability to secondary infections and mortality from all causes. These findings have been documented in multiple publications [87][88][89]. In general, the administration of corticosteroids to COVID-19 patients who were hospitalized was found to be advantageous solely for those who were undergoing invasive mechanical ventilation and oxygen therapy [90].
There are current debates surrounding the administration of renin-angiotensin-aldosterone system (RAAS) antagonists in individuals diagnosed with COVID-19. This is due to the virus's ability to attach to ACE2 receptors during cellular invasion. There is a debate among experts regarding the potential clinical advantages of inhibiting the RAAS, as some argue in favor of it while others have reservations about the possible upregulation of ACE2 that may result from such blockades. The present clinical data substantiate the recommendation of maintaining the RAAS antagonist treatment plan for authorized indications despite the occurrence of COVID-19 infection in patients at a later stage. This approach is endorsed by the Heart Failure Society of America, the American College of Cardiology, and the American Heart Association (AHA) [91]. In contrast, American Heart Association advise against administering nonsteroidal anti-inflammatory drugs (NSAIDs) to individuals with myocarditis due to their potential to induce renal impairment and sodium retention, which may worsen acute ventricular dysfunction [92].
It is crucial to conduct screening for any remaining cardiac involvement during the period of recovery in order to ascertain the magnitude of enduring cardiac ailments that may have been triggered by the COVID-19 infection. In the event that a considerable proportion of the population is discovered to be impacted, it may be fitting to initiate clinical trials of preventive treatments designed to avert enduring complications. The selection of screening tests for post-COVID-19 myocardial dysfunction and arrhythmias ought to be predicated on their respective categorization and cost-benefit analysis. Our suggestion is to perform routine ECG and echocardiogram assessments, supplemented by potential cardiac monitoring, within two to six months after recovery. However, it is important to note that these examinations may not identify minor clinical irregularities. In cases where initial testing reveals abnormalities or when there is a clinical indication, it is advisable to consider advanced imaging techniques such as MRI with gadolinium enhancement or echocardiographic strain. Subsequent research endeavors will elucidate whether a "post-COVID-19 cardiac syndrome" will emerge and the optimal approach for managing patients recuperating from COVID-19's cardiac implications [93].

Conclusions
Prolonged exposure to COVID-19 can result in serious cardiovascular symptoms such as myocarditis, arrhythmias, and myocardial damage. Due to the wide range of associated symptoms, conducting thorough examinations of patients is crucial while keeping in mind the varying ways in which they may manifest. Inflammatory markers present in blood tests have been found to be closely linked with illness severity, but negative troponin outcomes cannot completely rule out myocarditis. However, consistent high-sensitivity cardiac troponin tests are beneficial for identifying this disease in its early stages. Cardiac MRI is currently the gold standard diagnostic test for myocarditis since it can detect edema, hyperemia, necrosis, and fibrosis in the heart muscle. Nevertheless, cardiac MRI cannot distinguish between viral infection-induced or immune system-driven inflammation.
Patients who develop myocarditis after contracting long COVID have an unfavorable prognosis due to immune system dysfunction that causes irreparable tissue damage through fibrosis and microangiopathy. It is therefore imperative to identify cardiac involvement early on so that affected patients may receive cardioprotective medication and monitoring as necessary. The enhancement of treatment for long COVID syndrome patients experiencing cardiac issues can be facilitated through collaborative efforts among experts from diverse fields, such as pulmonology, cardiology, and infectious disease. Nonetheless, the comprehension of myocarditis or myocardial injury's underlying mechanisms in long COVID syndrome patients and the identification of potential therapeutic targets necessitate further investigation. The execution of initiatives to promote COVID-19 vaccination and preventive measures holds promise in mitigating the incidence of long COVID syndrome and its accompanying cardiac complexities in public health. This approach could assist in averting and advancing the early management of cardiac complications, resulting in improved outcomes for survivors impacted by COVID-19.

Conflicts of interest:
In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.